Replies to post #220659 on Avid Bioservices Inc (CDMO)

[biopharm]

I'm impressed as well.

I am very impressed that a few of these guys are on this panel that we know are 100% associated with Peregrine Pharmaceuticals/PS Targeting and yet been super quiet. Now they find themselves on a panel where they will be directly involved in verifying why and how PS Targeting works and its all scientifically proven. I hope the DMC is forewarned why the Bavi arm would possibly be working so much better vs the placebo arm.

The panel includes:

Scott J. Antonia, M.D., Ph.D., Department Chair, Program Leader, Thoracic Oncology Department Associate Professor Department of Interdisciplinary Oncology and Program Leader of the Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Dmitry I. Gabrilovich, M.D., Ph.D., Christopher M. Davis Professor in Cancer Research, and Program Leader, Translational Tumor Immunology, The Wistar Institute, Philadelphia, Pennsylvania

Kathy D. Miller, M.D., Ballve Lantero Scholar in Oncology, Professor, Department of Medicine, Co-Director, Simon Cancer Center Breast Cancer Program, Indiana University School of Medicine, Indianapolis, Indiana

Dmitriy Zamarin, M.D., Ph.D., Assistant Attending Physician, Gynecologic Medical Oncology and Immunotherapeutics, Memorial Sloan Kettering Cancer Center, New York, New York

Matthew D. Hellman, M.D., Assistant Attending Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York

Alexander M. Lesokhin, M.D., Assistant Member, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center, New York, New York

Rolf A. Brekken, Ph.D., Effie Marie Cain Research Scholar in Angiogenesis Research, Professor, Departments of Surgery and Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas
About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.

CONTACT: Christopher Keenan
Peregrine Pharmaceuticals, Inc.
[phone]
[e-mail]
Peregrine Pharmaceuticals, Inc. Logo